Published online Jul 18, 2014. doi: 10.5312/wjo.v5.i3.247
Revised: May 19, 2014
Accepted: May 29, 2014
Published online: July 18, 2014
Core tip: The study of agents active on bone formation is the main objective in the treatment of severe osteoporosis. rhparathyroid hormone (rhPTH) decreases vertebral, but not nonvertebral, fractures. On the contrary, antagonists of Wnt-inhibitors, that exert their effects mostly through a bone remodeling-independent mechanism, open new perspectives to improve not only trabecular bone but also cortical bone, with potential positive effect also on nonvertebral fractures incidence. The perspective in osteoporosis treatment should be more effective and better tolerated therapies aimed at minimizing individually fractures risk.